Director/PDMR Shareholding
Director/PDMR Shareholding
04 February 2026
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce that Adam Reynolds, Chairman of the Company, has acquired 150,000 ordinary shares of 0.05p each in the Company ("Ordinary Shares") at a price of 8p per share.
Following this acquisition, Adam Reynolds is interested in Ordinary Shares as follows:
|
Name |
Number of |
Resultant |
% |
|---|---|---|---|
|
Adam Reynolds |
150,000 |
442,857 |
0.28 |
Further information about the acquisition of Ordinary Shares is set out in the table below.
For further information, please contact:
|
ProBiotix Health plc Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations |
https://probiotixhealth-ir.com |
||
|
AlbR Capital Limited Aquis Corporate Adviser and Broker |
Tel: 020 7469 0930 |
||
|
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. |
||||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||
|
a) |
Name |
Adam Reynolds |
||
|
2 |
Reason for the notification |
|||
|
a) |
Position/status |
Chairman |
||
|
b) |
Initial notification /Amendment |
Initial |
||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor |
|||
|
a) |
Name |
ProBiotix Health plc |
||
|
b) |
LEI |
98450048683CF0388C30 |
||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||
|
a) |
Description of the financial instrument, type of instrument Identification code |
ordinary shares of 0.05p each ISIN: GB00BLNBFR86 |
||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares |
||
|
c) |
Price(s) and volume(s) |
150,000 shares at 8p per share |
||
|
d) |
Aggregated information - Aggregated volume - Price |
n/a - single transaction |
||
|
e) |
Date of the transaction |
3 February 2026 |
||
|
f) |
Place of the transaction |
Aquis Growth Market |
||
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
Aquis-listed ProBiotix Health
taps into demand for
cardiovascular disease treatments
Stephen O'Hara | 23
February 2023
IG UK | Youtube